Medline (NASDAQ:MDLN – Get Free Report) shares saw strong trading volume on Wednesday. Approximately 17,499,610 shares changed hands during trading, an increase of 124% from the average daily volume of 7,795,192 shares. The stock last traded at $38.8150 and had previously closed at $37.68.
Analyst Upgrades and Downgrades
Several research analysts have recently issued reports on the stock. BTIG Research restated a “buy” rating and issued a $55.00 target price on shares of Medline in a report on Thursday, November 5th. Stifel Nicolaus reduced their target price on Medline from $50.00 to $45.00 and set a “buy” rating on the stock in a research report on Thursday, August 6th. Bank of America lowered their price target on Medline from $53.00 to $46.00 in a report on Thursday, August 6th. Barclays cut their target price on Medline from $45.00 to $43.00 and set an “overweight” rating on the stock in a research report on Friday, October 9th. Finally, Wall Street Zen raised shares of Medline from a “hold” rating to a “buy” rating in a report on Saturday, November 7th. Twenty-three research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $46.08.
Check Out Our Latest Stock Report on MDLN
Medline Stock Performance
The company has a quick ratio of 2.51, a current ratio of 4.04 and a debt-to-equity ratio of 0.65. The company has a market cap of $50.99 billion and a P/E ratio of 88.11. The stock’s 50-day moving average price is $35.39 and its 200 day moving average price is $39.31.
Medline (NASDAQ:MDLN – Get Free Report) last posted its earnings results on Wednesday, November 4th. The company reported $0.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.32 by $0.12. The company had revenue of $7.86 billion during the quarter. Medline had a net margin of 1.84% and a return on equity of 8.21%. As a group, research analysts expect that Medline will post 1.58 EPS for the current fiscal year.
Insider Activity at Medline
In related news, major shareholder Private Ltd Gic sold 2,088,987 shares of the firm’s stock in a transaction on Tuesday, October 6th. The shares were sold at an average price of $35.05, for a total value of $73,218,994.35. Following the completion of the transaction, the insider owned 16,453,806 shares of the company’s stock, valued at approximately $576,705,900.30. This trade represents a 11.27% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold a total of 6,348,676 shares of company stock valued at $224,525,137 over the last 90 days. Insiders own 0.81% of the company’s stock.
Institutional Trading of Medline
A number of hedge funds have recently modified their holdings of the stock. GAMMA Investing LLC boosted its position in shares of Medline by 68.3% in the second quarter. GAMMA Investing LLC now owns 626 shares of the company’s stock valued at $25,000 after acquiring an additional 254 shares during the period. Allworth Financial LP lifted its stake in Medline by 36.8% during the third quarter. Allworth Financial LP now owns 1,439 shares of the company’s stock worth $50,000 after purchasing an additional 387 shares during the last quarter. Covestor Ltd raised its stake in shares of Medline by 31.8% during the third quarter. Covestor Ltd now owns 1,953 shares of the company’s stock valued at $68,000 after acquiring an additional 471 shares during the last quarter. NewEdge Advisors LLC increased its position in shares of Medline by 100.0% during the second quarter. NewEdge Advisors LLC now owns 950 shares of the company’s stock worth $37,000 after buying an additional 475 shares during the period. Finally, Reyes Financial Architecture Inc. acquired a new position in shares of Medline during the third quarter valued at about $30,000.
About Medline
Medline is a healthcare products manufacturer and distributor serving providers across the care continuum. Its customers include hospitals, surgery centers, physician practices, long-term care facilities and home-care organizations. The company offers a broad range of medical and surgical supplies, including products for infection prevention, wound care and patient care, as well as apparel and equipment. Medline also provides supply-chain and logistics services to healthcare organizations. Founded in 1966, Medline is headquartered in Northfield, Illinois, and serves customers in the United States and internationally.
Featured Articles
- Five stocks we like better than Medline
- 5 Consumer Discretionary Plays Showing Strength During the Tech Sell-Off
- NVIDIA’s Earnings Were Strong, But Can the Next CEO Keep the Momentum Going?
- SpaceX’s Historic Starship Catch Raises a Bigger Question About Its AI Spending
- AMD Bets $8.2B on Physical AI: Could Robotics Be Its Next Growth Frontier?
Receive News & Ratings for Medline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medline and related companies with MarketBeat.com's FREE daily email newsletter.
